ライフサイエンスコーパス: refractory disease

1 volume (TMTV) could detect early relapse or refractory disease.

2 b-based option is reasonable for relapsed or refractory disease.

3 improved tumour control and reduced rates of refractory disease.

4 dditional therapeutic choices to consider in refractory disease.

5 ed clonal expansion in patients with steroid-refractory disease.

6 ology will aid in treatment of a complex and refractory disease.

7 , particularly for patients with advanced or refractory disease.

8 may identify additional treatment options in refractory disease.

9 hese patients was 2 (range, 0-5) and 43% had refractory disease.

10 ole in the treatment of cancer patients with refractory disease.

11 herapy has been studied to address treatment-refractory disease.

12 promising therapeutic option in this highly refractory disease.

13 d in all CTCL stages as well as in treatment-refractory disease.

14 r patients with advanced stage and treatment-refractory disease.

15 al settings, frequently resulting in chronic refractory disease.

16 ensitive disease, and 18 were allografted in refractory disease.

17 ate cancer, in particular those with hormone-refractory disease.

18 develop the new variants present in hormone-refractory disease.

19 (H), and of 25% in patients with fludarabine-refractory disease.

20 r later therapy or in patients with platinum-refractory disease.

21 calized prostate cancer remains an extremely refractory disease.

22 cancer in both hormone-sensitive and hormone-refractory disease.

23 ovide outstanding local-regional control for refractory disease.

24 be effective therapeutic agents for steroid-refractory disease.

25 of ibrutinib in a population with rituximab-refractory disease.

26 ed to novel treatment strategies for steroid-refractory disease.

27 peutic options for patients with relapsed or refractory disease.

28 nificant challenges remain for recurrent and refractory disease.

29 of greater than 60% in patients with steroid-refractory disease.

30 reclinical models and patients with relapsed refractory disease.

31 ion has been proposed as salvage therapy for refractory disease.

32 and warrants investigation in patients with refractory disease.

33 of initial therapy and in the management of refractory disease.

34 ents with NSCLC, including 142 patients with refractory disease.

35 relieve the symptoms of advanced, medically refractory disease.

36 ion method to identify cured versus fatal or refractory disease.

37 chemotherapy should be reserved for hormone-refractory disease.

38 y because of the development of progressive, refractory disease.

39 apy and may serve as a diagnostic marker for refractory disease.

40 activation of androgen signaling in hormone refractory disease.

41 outcomes of patients with poor-risk primary refractory disease.

42 f MDR prior to selection and/or induction of refractory disease.

43 , few have demonstrated activity in platinum-refractory disease.

44 y in asthmatics with neutrophilia and severe refractory disease.

45 trated to be efficacious in the treatment of refractory disease.

46 antiangiogenic properties, in patients with refractory disease.

47 tastases (n = 62) from patients with hormone-refractory disease.

48 92 with Crohn's disease required surgery for refractory disease.

49 Cyclosporine A was effective for refractory disease.

50 ete remissions in patients with chemotherapy refractory disease.

51 particularly when colectomy is performed for refractory disease.

52 he time of initiation of salvage therapy for refractory disease.

53 eatment step 4 to 5 asthma, and 13 of 17 had refractory disease.

54 roduced responses in patients with relapsed, refractory disease.

55 activity may be effective in combating this refractory disease.

56 markers in both treatment-naive and relapsed/refractory disease.

57 biomarker for new therapeutic approaches to refractory disease.

58 viously untreated CLL and 16 had relapsed or refractory disease.

59 role in patients with high-risk or relapsed/refractory disease.

60 n favor of tumor cell survival and treatment-refractory disease.

61 fication was common in primary resistant and refractory disease.

62 uding with cells from patients with relapsed/refractory disease.

63 andard of care for patients with relapsed or refractory disease.

64 ll-tolerated in older patients with relapsed/refractory disease.

65 to identify imaging findings associated with refractory disease.

66 options are needed particularly for severe, refractory disease.

67 oved responses at first line and in relapsed/refractory disease.

68 seases could be considered for patients with refractory disease.

69 men is typically recommended for relapsed or refractory disease.

70 disease, and five patients (9%) had primary refractory disease.

71 in particular effective agents to treat TKI-refractory disease.

72 every 21 days (R-CHOP21) relapse or develop refractory disease.

73 targeted drugs in patients with radioiodine-refractory disease.

74 rapies and induce remission in patients with refractory disease.

75 (>/=1 lymph nodes >/=5 cm), and 37 (58%) had refractory disease.

76 oma by prevention or successful treatment of refractory disease.

77 of tandem autologous transplant in breaking refractory disease.

78 explore its effects on transition to hormone-refractory disease.

79 zole) have been demonstrated to be useful in refractory disease.

80 being more heavily pretreated and with more refractory disease.

81 with emphasis on juvenile disease and adult refractory diseases.

82 xploration of nelarabine against fludarabine-refractory diseases.

83 1 to 16 years of age (relapsed disease, 19; refractory disease, 10) received gemtuzumab ozogamicin r

84 18%; P = .05) and in those who had platinum-refractory disease (25% v 15%; P = .14).

85 ziv-aflibercept in patients who had platinum-refractory disease (27% v 10%; P = .02) but not in patie

86 an 5 [range 2-14] prior regimens), treatment-refractory disease (70%), unmutated IGHV (91%), and del1

87 tinum-resistant disease, and 13 had platinum-refractory disease (according to platinum-free interval)

88 PR) after first transplant in eight, and (4) refractory disease after first transplant in two.

89 ly a subset of patients develop recurrent or refractory disease after first-line treatment.

90 All patients had relapsed or refractory disease after previous treatment with a BCR s

91 second transplant) who achieved a PR or had refractory disease after the first transplant.

92 er, in metastases from patients with hormone-refractory disease, amplification of the androgen recept

93 Patients were required to have relapsed/refractory disease, an absolute neutrophil greater than

94 27 patients were diagnosed with relapsed or refractory disease and 12 died.

95 90%), including 2 patients with blinatumomab-refractory disease and 15 who had undergone stem-cell tr

96 th activity in CLL patients with fludarabine-refractory disease and 17p deletion.

97 Thirty-eight percent had refractory disease and 29% a Karnofsky performance score

98 pression is strongly associated with hormone-refractory disease and advanced tumor stage in prostate

99 ents with adverse prognostic factors such as refractory disease and increased beta2-microglobulin, pa

100 chronic disease ranging from mild to severe refractory disease and is classified into various clinic

101 Patients with refractory disease and LG-NHL did not benefit from a sec

102 ic B-ALL patients with multiply relapsed and refractory disease and normal karyotype or low risk cyto

103 ons exist; however, many patients experience refractory disease and novel treatments are needed.

104 However, refractory disease and the emergence of antigen-loss tum

105 use large B-cell lymphoma (DLBCL), including refractory disease and the second-line age-adjusted inte

106 CR, 2 after salvage therapy for relapsed or refractory disease, and 1 after alternative treatment fo

107 ear-CR, including several with anthracycline-refractory disease, and another 8 having partial respons

108 loss of NIS expression, function, or both in refractory disease, and discuss preclinical and clinical

109 reatment options for patients with rituximab-refractory disease are an important clinical need.

110 -Hodgkin lymphoma (NHL), relapses or primary refractory disease are commonly observed and associated

111 endence and effective treatments for hormone-refractory disease are described.

112 rophylaxis, initial therapy, and therapy for refractory disease are discussed.

113 erapy and in multiagent regimens in relapsed/refractory disease as well as frontline settings.

114 f patients with lenalidomide- and bortezomib-refractory disease as well as in patients with high-risk

115 2.23; 95% CI, 1.02-4.87), indicative of ACV-refractory disease, as independent risk factors for ACV(

116 Relapsed/refractory disease at CBT, recipient HLA-C2/C2 genotype,

117 Relapsed/refractory disease at study entry, TP53 aberration, adva

118 t within the previous 3 months, did not have refractory disease, autoimmune haemolytic anaemia requir

119 fferentiated thyroid cancer have radioiodine-refractory disease, based on decreased expression of the

120 lantation, high lactate dehydrogenase (LDH), refractory disease, bone marrow involvement, low perform

121 ty was observed in patients with fludarabine-refractory disease, bulky adenopathy, and del(17p) CLL.

122 The RICs offer significant potency, even in refractory disease, but their complexity may limit their

123 innovations for countering heterogeneous and refractory disease by virtue of their ability to bind tw

124 Neuropathic pain is a refractory disease characterized by maladaptive changes

125 ression from clinically localized to hormone refractory disease, coinciding with an increase in Akt a

126 ment practices vary widely and management of refractory disease continues to be challenging.

127 Seven (47%) of 15 patients with rituximab-refractory disease demonstrated reduction in their tumor

128 , or transformed follicular lymphoma who had refractory disease despite undergoing recommended prior

129 t outcome, 65% of patients with relapsed and refractory disease do not respond.

130 1) ocular disorders, may pose a risk for ACV-refractory disease due to ACV resistance.

131 long-term ACV prophylaxis predisposes to ACV-refractory disease due to the emergence of corneal ACV(R

132 s and the need for effective drugs in highly refractory disease, etirinotecan pegol may warrant furth

133 se (>1.5 cm) by CT scan, and had relapsed or refractory disease following one or more previous lines

134 l-cell lung cancer, all of whom had platinum-refractory disease, had a partial response or prolonged

135 is efficacious in patients with relapsed or refractory disease harboring MYD88 L265P mutation.

136 Patients with refractory disease, history of bowel obstruction, or > t

137 rter with mitumprotimut-T/GM-CSF in relapsed/refractory disease (HR = 2.265; P = .004).

138 Nineteen (76%) had refractory disease immediately before enrollment.

139 ough benefit was first shown in relapsed and refractory disease, improved overall response, duration

140 eting CD19 induced lasting remission of this refractory disease in a number of patients.

141 (MM); however, 65% of patients with relapsed refractory disease in a phase II study do not respond to

142 st indicators of aggressive and chemotherapy-refractory disease in children with neuroblastoma, the m

143 Gorlin syndrome and nonmetastatic BCCs, but refractory disease in distantly metastatic tumors has no

144 tes with the progression to advanced hormone refractory disease in patient samples.

145 xist, which might contribute to recurrent or refractory disease in some patients.

146 cases include those individuals with hormone-refractory disease in the absence of clinical metastases

147 possibly prevent the emergence of bortezomib-refractory disease in the clinic.

148 patients, it is of paramount importance for refractory disease in view of the longer duration of pan

149 reased rapidity of periodontal bone loss and refractory disease incidence in smokers.

150 for the development of AR-dependent hormone-refractory disease, including changes in expression of A

151 depletion could be useful for patients with refractory disease, including lupus nephritis, and antib

152 in seven (70%) of 10 patients with pazopanib-refractory disease, including one patients with RCC with

153 patients, 636 were included on the basis of refractory disease inclusion criteria.

154 Progression of prostate cancer to androgen-refractory disease is correlated with increased expressi

155 le in the treatment of patients with primary refractory disease is not well defined.

156 Progression to hormone refractory disease is often correlated with overexpressi

157 notherapy, but with relapses with treatment, refractory disease is the most common outcome, especiall

158 Although hormone-refractory disease is unresponsive to androgen-deprivati

159 mized trial has been conducted for recurrent/refractory disease, leaving many questions unanswered ab

160 emain the mainstay of therapy; patients with refractory disease may respond to other immunomodulating

161 tional Institutes of Health score "severe"), refractory disease (median treatments = 4).

162 DCT as third-line or later therapy, platinum-refractory disease, mediastinal primary tumor site, nons

163 of adult and juvenile myositis patients with refractory disease met the DOI.

164 t, clinicians treating patients with hormone-refractory disease must weigh the benefits of earlier ch

165 outcomes for some patients with relapsed and refractory disease, not all patients have access to thes

166 Food and Drug Administration for relapsed or refractory disease of B-cell lineage.

167 Patients with PTCL with primary refractory disease or early relapse have extremely poor

168 dies between 1993 and 2007 were screened for refractory disease or relapse (RR-HL).

169 ment with ibrutinib or other BTK inhibitors, refractory disease or relapse within 24 months with a pr

170 patients can require colectomy for medically refractory disease or to treat colonic neoplasia.

171 a were aged 18 years of age or older and had refractory disease or were in first relapse after one or

172 s aged 18 years or older who had relapsed or refractory disease or were ineligible for standard treat

173 eal ACV(R) isolate was a risk factor for ACV-refractory disease (OR 2.28; 95% CI, 1.06-4.89).

174 ith poor prognostic features, with primarily refractory disease, or with relapsed disease following c

175 lymph node metastasis (P = 0.0002), hormone-refractory disease (P < 0.0001), presence of ERG gene fu

176 ysis were baseline MTV (bMTV) (P < .001) and refractory disease (P = .003).

177 esonide are helpful in patients with steroid-refractory disease, particularly in those with gastroint

178 For refractory disease, patients were randomized between rab

179 Patients were stratified by relapsed versus refractory disease, presence or absence of del(17p) or T

180 Of 6 patients with refractory disease prior to treatment, 2 had complete re

181 Responses were seen in patients with prior refractory disease, prior ASCT, and prior alloSCT; howev

182 apse or progression, or first designation of refractory disease, provided organ function requirements

183 ia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity.

184 hich treatment of patients with relapsed and refractory disease remains a challenge.

185 d-line treatments for advanced relapsing and refractory disease remains a priority.

186 the treatment of patients with relapsed and refractory disease remains challenging.

187 ue sarcomas, however, prognosis for advanced refractory disease remains poor.

188 Hormone refractory disease represents a late-stage and generally

189 For patients with steroid-refractory disease, response to second-line treatment is

190 In relapsed or refractory disease, selected compounds appear to have ac

191 and durability of remission in the relapsed/refractory disease setting.

192 Advanced and platinum-refractory disease states continue to be challenging ent

193 Advanced and platinum-refractory disease states continue to be challenging ent

194 treatment of Hodgkin Lymphoma, patients with refractory disease still have a poor prognosis.

195 linical course and inevitable development of refractory disease, stressing the need to develop altern

196 of patients with chemotherapy- and rituximab-refractory disease, suggesting that bendamustine may be

197 ic drug in patients with mainly relapsed and refractory disease suggests that haematological response

198 The high response rate in refractory disease suggests that this agent may be usefu

199 Temporomandibular joint (TMJ) ankylosis is a refractory disease that is difficult to predictably trea

200 Relapsed or refractory disease that is resistant to ATRA is a clinic

201 in patients with early-relapsing or primary refractory disease, the ORR was 55% and CR 30%.

202 Patients with radioiodine-refractory disease, therefore, are not amenable to (131)

203 the critical roles that GAS6 and AXL play in refractory disease, this signaling axis represents an at

204 improvement in OS was noted in patients with refractory disease treated with amrubicin.

205 We report 4 patients with refractory disease treated with rituximab who had clinic

206 Ten patients had primary refractory disease, two were in first remission, and two

207 with unresponsive, high-risk disease because refractory disease typically retains radiation sensitivi

208 ne treatment for ITP; however, patients with refractory disease usually require splenectomy.

209 Outcome for patients who had recurrent or refractory disease was poor: only four (22%) patients ac

210 ho did not proceed to transplantation due to refractory disease were considered transplantation failu

211 radius and identifying trials for recurrent/refractory disease were documented as challenges for pat

212 ent or vincristine/doxorubicin/dexamethasone-refractory disease were eligible for the phase II multi-

213 augICE for relapsed/refractory HL, bMTV and refractory disease were independent prognostic factors f

214 with either rituximab-sensitive or rituximab-refractory disease who had at least a partial response.

215 atic cholangiocarcinoma (ICC) is a treatment-refractory disease with a dismal outcome.

216 Patients and Methods Patients with RAI-refractory disease with Response Evaluation Criteria in

217 s who are appropriately shown to have iodine-refractory disease, with 1 drug approved by the Food and